Kennedy's Vaccine Trial Clears Denmark Ethics Hurdle, Testing Regulatory Arbitrage in West Africa

A $1.6 million U.S.-backed vaccine trial withholding hepatitis B shots from African newborns has cleared its final ethical hurdle in Denmark, exposing deep fractures in global health governance and marking a watershed moment for the Trump administration's vaccine agenda. The study, championed by U.S. Health Secretary Robert F Kennedy Jr and approved by a Danish university ethics committee this week, will proceed in Guinea-Bissau despite four committee resignations and fierce opposition from infectious disease specialists .

14,000 infants will be enrolled in the trial designed by Danish researchers Peter Aaby and Christine Stabell Benn. Half will receive the hepatitis B vaccine at birth. The other half will have the recommended dose withheld for six weeks, a design critics describe as placing children in a "lottery" where losing means exposure to a virus that causes irreversible liver damage and cancer when contracted in infancy .

The trial received approval from the University of Southern Denmark's ethics committee despite unprecedented dissent. Stig Børsen Hansen, a founding committee member who reviewed the study, resigned immediately after the vote, telling The Guardian that children randomly assigned to the unvaccinated group face infection "by design" as part of the research protocol . Three other members followed him out the door.

Why this matters beyond Guinea-Bissau

This trial represents the first operational test of Kennedy's vaccine philosophy using federal dollars, with the Centers for Disease Control and Prevention allocating the $1.6 million in matching funds alongside private capital from billionaire Bill Ackman's Pershing Square Foundation and the Bluebell Foundation . Paul Offit, an infectious disease physician at Children's Hospital of Philadelphia, framed the stakes bluntly: Kennedy "wants to make it so we don't use a birth dose here in this country. That's the goal" . The trial's design, which Offit said would never clear U.S. ethical review, exploits regulatory arbitrage by conducting research in a developing nation that American institutions would reject domestically.

The Protocol Revision That Changed Nothing Material

The Danish research team modified the study protocol after international outcry earlier in 2026, when Guinea-Bissau Health Minister Quinhin Nantote initially suspended the project . The revision now requires researchers to test mothers for hepatitis B before birth. Infants born to positive mothers will receive the vaccine and be excluded from the trial. Only babies of mothers testing negative may be enrolled in the randomized study .

The adjustment addresses vertical transmission but ignores community exposure pathways. Hepatitis B survives on surfaces for seven days and transmits through shared household items including washcloths, toothbrushes, and fingernail clippers, according to clinical data cited by Offit . Previous research shows half of pediatric hepatitis B infections occur after birth through such exposures, not maternal transmission . In Guinea-Bissau, where 18 percent of adults carry the virus, one of the highest prevalence rates globally, newborns face exposure from fathers, siblings, extended family, and caregivers .

The screening protocol itself contains a statistical flaw that undermines its protective value. The hepatitis B test carries a 5 percent false negative rate, meaning some mothers with active infections will incorrectly test negative, and their babies will enter the unvaccinated study arm with zero protection despite high-risk exposure .

Regulatory Shopping and the Denmark Gambit

The trial's approval path reveals calculated forum-shopping. The University of Southern Denmark research ethics committee had never reviewed medical studies before this one but changed its rules specifically to evaluate the Guinea-Bissau protocol . Henrik Støvring, a professor of statistics and pharmacometrics at Aarhus University in Denmark, noted the irregularity: national ethics committees typically oversee medical research, but this study fell outside their jurisdiction because it takes place abroad .

The Helsinki Declaration requires ethics approval in both host and sponsor countries for international medical research. The Danish national committee, which handles medical studies, never reviewed this trial. The university committee that did approve it saw its members with medical expertise argue against proceeding, only to be outvoted by the majority .

Støvring observed that Denmark itself would be a superior research location. The country does not routinely give hepatitis B vaccines to newborns unless mothers test positive, for which all pregnant women are screened . This creates a natural comparison group without deliberately withholding recommended treatment. Yet the research proceeds in Guinea-Bissau, where the Bandim Health Project, operated by the Danish team for decades, maintains deep integration with the national health system . At least one senior Guinea-Bissau health official holds dual appointments with the research project, according to The Guardian .

The Institutional Capital Angle

The financial architecture behind this trial merges public health funding with private philanthropy in ways that insulate decision-makers from accountability. The CDC's $1.6 million allocation flows through standard appropriations, making it difficult for Congress to reverse without broader budget action. Pershing Square Foundation and Bluebell Foundation provide matching private capital, creating funding redundancy that buffers the project against single-source withdrawal .

Bill Ackman, the activist investor and Pershing Square co-founder, has taken prominent positions on pandemic policy and vaccine development in recent years, though neither he nor the foundations responded to questions from The Guardian about this specific trial . The mix of federal and philanthropic dollars creates competing accountability structures: the CDC answers to HHS under Kennedy's direction, while private foundations operate with minimal public oversight beyond tax-exempt status requirements.

This funding model parallels broader trends in global health financing, where bilateral government aid increasingly partners with large private foundations to pursue research agendas that may not clear traditional peer review or would face political obstacles if funded solely through public channels. The structure allows controversial research to proceed with official imprimatur while distributing reputational and financial risk across multiple institutions.

The Plocamium View

The Guinea-Bissau trial is not an isolated ethical lapse. It is a proof of concept. Kennedy's stated goal is eliminating the birth-dose hepatitis B vaccine recommendation in the United States, a position that contradicts decades of epidemiological data showing the shot prevents chronic infection and liver cancer when administered within 24 hours of birth . He cannot run this trial domestically, U.S. ethics boards would reject a study design that deliberately withholds standard-of-care treatment from newborns.

So he is outsourcing the research to a nation with weak regulatory infrastructure, using a combination of CDC funding and private capital to create institutional insulation. If the trial proceeds to completion and the data can be interpreted to support vaccine skepticism, regardless of statistical validity or confounding variables, it provides Kennedy with a peer-reviewed publication he can cite when pushing to change U.S. vaccine policy. The research subjects are African infants, the beneficiaries of any policy change would be American parents seeking to avoid vaccination, and the costs of failure, measured in pediatric hepatitis B infections, chronic liver disease, and cancer, will be borne entirely by Guinea-Bissau.

This is regulatory arbitrage applied to human subjects research. The same principle that drives corporations to conduct drug trials in countries with lower ethical standards now applies to the U.S. government's own vaccine policy agenda. The Trump administration's approach to global health, visible in this trial and in recent energy diplomacy with Russia that prioritized domestic fuel prices over Ukrainian security, consistently subordinates international norms and partner-nation interests to immediate political objectives.

Four ethics committee members resigned in protest, but the trial proceeds . That tells institutional investors everything they need to know about enforcement mechanisms in international research governance. The Helsinki Declaration has no teeth. National ethics boards can be circumvented through jurisdictional maneuvering. Private funding can be layered with public dollars to create structures resistant to oversight. The reputational risk that typically constrains controversial research dissipates when the research occurs in a country most Western media outlets cover sporadically and when the institutional actors can point to each other when accountability questions arise.

The second-order effect matters more than this single trial. If the Denmark-Guinea-Bissau model succeeds, expect proliferation. Any research agenda that faces domestic ethical constraints can be exported, provided the sponsor can find a host nation with aligned interests or sufficient financial incentives and an ethics review structure willing to accommodate the study design. The Trump administration, which has shown willingness to impose emergency rule in allied nations when politically expedient and sanction international legal bodies that challenge U.S. policy, has demonstrated that traditional diplomatic constraints no longer bind policy decisions.

So What: The New Global Health Order

The Guinea-Bissau trial marks an inflection point in how powerful nations conduct health research in the Global South. The post-World War II framework, built on Nuremberg Code principles and reinforced by the Helsinki Declaration, assumed that wealthy sponsor nations would apply domestic ethical standards to international research. That assumption is dead.

Institutional investors should track three specific implications. First, pharmaceutical and biotech companies now operate in an environment where government-backed research can proceed with ethical standards below what industry would accept, creating both reputational risk through association and competitive risk if controversial government trials generate data that influences regulatory policy. Second, the integration of private philanthropic capital with federal funding in politically sensitive research creates new due diligence requirements for allocators. Foundation investments in global health now carry execution risk tied to the political agendas of current administrations. Third, the collapse of international research ethics enforcement mechanisms removes a constraint on the pace of clinical development, but it also eliminates a quality signal. Studies that proceed despite ethics committee resignations and expert opposition will generate data, but that data will be contested, limiting its utility for regulatory submissions or evidence-based policymaking.

The trial will enroll 14,000 infants . Some will contract hepatitis B who would not have if they had received the vaccine at birth. That outcome is not a research accident. It is the study design. And it received approval from institutions backed by the United States government and prominent Western philanthropists. That fact should recalibrate expectations about what constraints, if any, govern the Trump administration's approach to global health policy in its third year.